rhIL-11 seems to be widely used in China for Chemotherapy-Induced Thrombocytopenia, but some papers I read demonstrate that rhIL-11 has limited use because of its side effect, I'd like to know how it is used outside China. is thereany one to help?
I don't have experience with rhIL-11 (Oprelvekin) because it is not available in Thailand (Non-Thai FDA Approval) from the literature dose 50 mcg/kg Sc once daily 10-21 days. The side effects quite different from GCSF, such as hypersensitivity reactions, fluid retention, arrhythmia and anemia. But I familiar with eltrombopag and romiplostim the efficacy of these agents are difficult to evaluate, our physicians use in many cases with heavily chemotherapy treatment. And need to check drug-drug interaction and platelet count closely.
Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia].
Sun XF1, Guan ZZ, Huang H, Zhou QH, Yi C, Zhang LJ, Zhu J, Li R, Zhou J, Zhang M, Guo Y.
Abstract
BACKGROUND AND OBJECTIVE:
Cancer chemotherapy can induce thrombocytopenia. It is necessory to develop drugs that can prevent and treat thrombocytopenia. The current study was designed to evaluate the efficacy and toxicity of rhIL-11 in prevention and treatment of chemotherapy-induced thrombocytopenia.
METHOD:
A total of 109 cancer patients were involved randomly into AB or BA group and every patient received 2 cycles of chemotherapy. IL-11 was administered subcutaneously(50 micrograms/kg/d), beginning 24 hours after completion of chemotherapy for 14 consecutive days or continuing until platelet count was > 400 x 10(9)/L during cycle A. Patients did not received IL-11 during cycle B. Another 41 cases of cancer patients whose platelet were less than 50 x 10(9)/L after chemotherapy entered into open study group. IL-11 administration was the same as above.
RESULTS:
Efficacy can be evaluated in 107 cases in controlled study group. Mean platelet count of cycle A was (246.49 +/- 88.64) x 10(9)/L and cycle B was (180.24 +/- 83.34) x 10(9)/L(P = 0.000). Grade III/IV thrombocytopenia in cycle A and cycle B were 7/107(6.5%) and 15/107(14%), respectively (P = 0.04). The minimum platelet counts were (136.46 +/- 74.64) x 10(9)/L and (107.77 +/- 61.33) x 10(9)/L, respectively (P = 0.000). The maximum platelet counts were (381.28 +/- 150.39) x 10(9)/L and (207.44 +/- 113.32) x 10(9)/L, respectively (P = 0.000). For open study group, 32 patients could be evaluated. The platelet count increased from(30.1875 +/- 12.13) x 10(9)/L to (226.25 +/- 163.91) x 10(9)/L after IL-11 administration. Major adverse effects were edema, dizziness, palpitation, etc.
http://www.ncbi.nlm.nih.gov/pubmed/12478901
haven't been online for a long time! thank you so much for your answer!
I checked Pubmed, and found few clinical trials (after 2000 ) cocerning about the use of rhIL-11 for Chemotherapy Induced Thrombocytopenia, the studies I found were mainly conducted in China.
- Badges
- Science topic